T-DXd ‘Active’ Against HER2-Positive Breast Cancer Brain Metastases
From ESMO Breast Cancer 2022:
Trastuzumab deruxtecan may help control intracranial metastases in patients with HER2-positive breast cancer
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
From ESMO Breast Cancer 2022:
Trastuzumab deruxtecan may help control intracranial metastases in patients with HER2-positive breast cancer
Metastatic hormone receptor-positive, HER2-negative breast cancer patients may respond to sacituzumab govitecan
Circulating tumour DNA testing can help identify breast cancer mutations with targetable therapies
Adding pembrolizumab to eribulin does not improve the outcome of patients with HR-positive, HER2-negative metastatic breast cancer
eXalt3 trial findings indicate ensartinib may improve progression-free survival for patients with advanced ALK-rearranged non-small-cell lung cancer
Early results suggest benefit of dual PARP and PD-L1 inhibition in metastatic breast cancer patients carrying germline BRCA mutations
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.